Review
Immunology
Ken Maes, Anna Mondino, Juan Jose Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Karine Breckpot
Summary: Cancer cells can evade the immune system through epigenetic alterations, but epigenetic modulating agents have the potential to restore immunological fitness and overcome peripheral tolerance to transformed cells. By acting on both cancer cells and immune cells, EMAs represent interesting strategies for combinatorial therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Microbiology
Yonathan Arfi, Carole Lartigue, Pascal Sirand-Pugnet, Alain Blanchard
Summary: Mycoplasmas are small, genome-reduced bacteria with the ability to colonize a wide range of host species. They can exist as commensal microbiota or cause pathogenic inflammatory diseases. These bacteria have evolved strategies to evade the host's immune response, including the expression of immunoglobulin-binding proteins to prevent antibody-antigen interaction. Understanding these immune evasion mechanisms is crucial for studying mycoplasma diseases and improving vaccine efficacy.
Article
Genetics & Heredity
Hongbin Zhang, Zaifa Hong, Peipei Li, Han Jiang, Pengfei Wu, Jinzhong Chen
Summary: This study constructed an immune evasion-related gene signature (IEVSig) based on 182 immune evasion-related genes to predict the prognosis of colon cancer patients and provide insights into therapeutic strategies. Patients with high IEVSig had higher TNM stage, shorter recurrence-free survival, increased immune cell infiltration, and poorer response to immunotherapy compared to patients with low IEVSig.
FRONTIERS IN GENETICS
(2022)
Review
Oncology
En-Si Ma, Zheng-Xin Wang, Meng-Qi Zhu, Jing Zhao
Summary: This review systematically summarizes the intricate crosstalk between gastric cancer cells and immune cells, and how gastric cancer cells alter immune cells to create an immunosuppressive microenvironment. It also highlights the promising survival advantages of immune checkpoint inhibitor-based immunotherapies in gastric cancer patients.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Review
Oncology
Rosy Njonkou, Christopher M. Jackson, Graeme F. Woodworth, David S. Hersh
Summary: This review explores the immune evasion mechanisms in pediatric glioblastoma and highlights potential opportunities for implementing immunotherapy in the treatment of these devastating brain tumors.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Cell Biology
Timo Burster, Rebecca Traut, Zhanerke Yermekkyzy, Katja Mayer, Mike-Andrew Westhoff, Joachim Bischof, Uwe Knippschild
Summary: The invasive nature of glioblastoma poses challenges to standard care, as conventional therapies have failed to completely eradicate glioblastoma cells. New approaches including small molecule inhibitors, immunotherapy, and virotherapy, focus on boosting the host immune system to interfere with immune evasion of glioblastoma cells, showing promise for therapeutic applications.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Immunology
Jacob R. Hambrook, Patrick C. Hanington
Summary: Human schistosomes have evolved various immune evasion strategies, such as molecular mimicry of host antigens and the utilization of an immune resistant outer tegument, to survive in both snail and human hosts. Understanding these mechanisms is crucial for the development of novel therapeutics and treatment plans.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Anup S. Pathania, Philip Prathipati, Kishore B. Challagundla
Summary: Recent advances in extracellular vesicle biology have highlighted the critical role of these vesicles in maintaining cell homeostasis and immune surveillance, particularly in the context of cancer research. Exosomes can influence cell communication by transferring biomolecules, impacting immune cell responses within the tumor microenvironment.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Review
Urology & Nephrology
Xiaoyang Wang, Robert Lopez, Rebecca A. Luchtel, Sassan Hafizi, Benjamin Gartrell, Niraj Shenoy
Summary: This article reviews the advancements in targeted therapies and immune checkpoint inhibitors in the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade, emphasizing the importance of understanding the mechanisms adopted by RCC cells to evade immune killing and exploring current clinical trials and future directions in the field.
KIDNEY INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Jimena Alvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena Gonzalez Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer
Summary: This study investigates the expression and therapeutic effects of CD24 and CD47, two immune checkpoints, in B-cell lymphoma. The results show that CD24 is associated with poor survival in MCL patients, while CD47 is associated with survival in DLBCL patients. CD24 antibody treatment exhibits potent phagocytic effects in MCL, but not in DLBCL.
Review
Microbiology
Dongyao Wang, Binqing Fu, Haiming Wei
Summary: HBV is a hepatotropic virus that can cause chronic infection and liver disease. Despite progress, a cure for HBV has not been found yet. Immune exhaustion and evasion are observed during CHB infection, but the mechanism is not fully understood. Recent studies suggest that improving the antiviral immune response may be the key to cure HBV, and combinations of new drugs and immunotherapies can be explored for this purpose.
Review
Oncology
Tingxun Lu, Jie Zhang, Zijun Y. Xu-Monette, Ken H. Young
Summary: Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, but a significant proportion of patients experience refractory or relapse. High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT) has been the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients, but patients who fail salvage treatment or are ineligible for auto-SCT have poor outcomes. Various immune-based therapies, such as monoclonal antibodies, chimeric antigen receptor T-cells, and immune checkpoint inhibitors, have been developed to expand treatment options for R/R DLBCL patients.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Summary: This study reveals that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity by indirectly inhibiting CD8(+) T cell infiltration, regardless of BRAF status. It is also found that Activin-A/INHBA expression is correlated with resistance to anti-PD1 therapy in melanoma patients and impairs response to combination anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Medicine, General & Internal
Kazuyuki Nakagome, Keishi Fujio, Makoto Nagata
Summary: Allergen immunotherapy (AIT) is a treatment for allergic diseases that involves administering clinical allergens to patients. It can modify allergen-specific immune responses and alleviate symptoms of allergic diseases such as asthma and rhinitis. AIT has also been shown to suppress sensitization to new allergens, indicating its potential in nonspecific suppression of allergic immune responses.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Alberto Cruz-Bermudez, Raquel Laza-Briviesca, Marta Casarrubios, Belen Sierra-Rodero, Mariano Provencio
Summary: The tumor microenvironment undergoes altered metabolic properties due to the needs of tumor cells, natural selection of adapted clones, and selfish relationships with other cell types. Metabolism not only supports uncontrolled tumor growth but also plays a key role in controlling tumor immune evasion. Despite revolutionizing cancer treatment, immunotherapy may not benefit all patients, leading to eventual relapse.
